AIM ImmunoTech reports positive Phase III data of Ampligen f

AIM ImmunoTech has reported positive initial pilot study data from its Phase III trial of an investigational drug, Ampligen, for long Covid.

Related Keywords

Thomas Equels , Electronic Data Capture Solutions For Clinical Trials , Contract Manufacturing Organisation , Contract Research Organisation For Clinical Trials , Drug Administration , Access Program , Expanded Access Program , Research Organisation , Manufacturing Organisation , Pharmaceutical Supply , Data Capture Solutions ,